Fallopian tube cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Fallopian tube cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal https://clinicaltrials.eu/trial/study-on-niraparib-carboplatin-and-paclitaxel-for-advanced-ovarian-cancer-patients-after-tumor-removal/ Wed, 29 Apr 2026 14:48:06 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-carboplatin-and-paclitaxel-for-advanced-ovarian-cancer-patients-after-tumor-removal/ This clinical trial is focused on studying the treatment of advanced high-grade ovarian cancer, including related conditions such as fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The study involves patients who have no remaining tumor mass after initial surgery. The treatment being tested is a medication called niraparib tosylate monohydrate, which is taken as a tablet. This medication is being compared to standard chemotherapy treatments, which include carboplatin and paclitaxel, both given as infusions through a vein.

The purpose of the study is to determine if taking niraparib after three cycles of chemotherapy is as effective as taking it after six cycles. The study will involve patients receiving either three or six cycles of chemotherapy, followed by maintenance treatment with niraparib. Some patients may receive a placebo instead of niraparib to compare the outcomes. The study aims to see if the shorter treatment duration can provide similar benefits in preventing cancer from returning.

Participants in the study will be monitored over time to assess their health and any side effects from the treatments. The study will also look at how long patients live without the cancer coming back and their overall survival rates. The trial will help determine the best approach to using niraparib in treating these types of cancer, potentially offering a more efficient treatment option for patients in the future.

]]> Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer https://clinicaltrials.eu/trial/study-on-adjusting-chemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-poor-prognostic-ovarian-cancer/ Wed, 29 Apr 2026 14:29:35 +0000 https://clinicaltrials.eu/trial/study-on-adjusting-chemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-poor-prognostic-ovarian-cancer/ This clinical trial is focused on studying ovarian cancer, specifically in patients who have a poor prognosis due to the cancer’s resistance to initial chemotherapy and incomplete surgical removal of the tumor. The study will explore the effectiveness of a new treatment approach using a combination of carboplatin and paclitaxel, which are chemotherapy drugs. These drugs are typically used to treat ovarian cancer, but this trial will test a new dosing schedule that involves more frequent, smaller doses, known as a “weekly dose-dense regimen.” The goal is to see if this new approach is more effective than the standard treatment, which involves larger doses given every three weeks.

In addition to carboplatin and paclitaxel, the study will also involve the use of bevacizumab, a medication that helps prevent the growth of blood vessels that supply the tumor, and filgrastim, which is used to boost white blood cell counts and help the body fight infections during chemotherapy. Some patients in the study will receive a placebo instead of bevacizumab to compare the effects. The trial aims to determine if the new treatment plan can improve outcomes for patients, such as increasing the chances of successful surgery and extending survival times.

Participants in the study will receive treatment over a period of up to 64 weeks. The study will monitor various outcomes, including the overall response to treatment, progression-free survival (the time during which the cancer does not get worse), and overall survival. The trial will also assess the quality of life of participants and gather information on any side effects experienced. The findings from this study could help improve treatment strategies for patients with ovarian cancer who have a poor prognosis.

]]>